---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-25-000115"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2025-10-22T23:59:59+00:00"
generated_at: "2026-05-17T02:44:53.485748+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nurix initiates pivotal Phase 2 DAYBreak trial of bexobrutideg in r/r CLL with 600 mg QD dose

## Summary
- DAYBreak Phase 2 will enroll ~100 r/r CLL/SLL patients after prior cBTKi, ncBTKi, and BCL-2i; primary endpoint is ORR by IRC.
- 600 mg QD dose selected via Phase 1b randomized cohort; aligned with FDA, MHRA, and EMA for accelerated approval pathway.
- Confirmatory Phase 3 trial planned for H1 2026 with ~400 patients comparing bexobrutideg to pirtobrutinib or chemoimmunotherapy.
- NX-1607 Phase 1a data showed disease control rate 49.3% in 82 patients; confirmed partial response in MSS colorectal cancer.
- Preclinical data presented claim superior degradation potency and selectivity across BTK mutations; investor webcast held Oct 22.

## SEC filing metadata
- accession: 0001549595-25-000115
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2025-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000115/0001549595-25-000115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000115/nrix-20251022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-25-000115
- JSON: https://secwatch.observer/filing/0001549595-25-000115.json
- Plain text: https://secwatch.observer/filing/0001549595-25-000115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.